An overview of space medicine.

Space medicine is fundamental to the human exploration of space. It supports survival, function and performance in this challenging and potentially lethal environment. It is international, intercultural and interdisciplinary, operating at the boundaries of exploration, science, technology and medicine. Space medicine is also the latest UK specialty to be recognized by the Royal College of Physicians in the UK and the General Medical Council. This review introduces the field of space medicine and describes the different types of spaceflight, environmental challenges, associated medical and physiological effects, and operational medical considerations. It will describe the varied roles of the space medicine doctor, including the conduct of surgery and anaesthesia, and concludes with a vision of the future for space medicine in the UK.Space medicine doctors have a responsibility to space workers and spaceflight participants. These 'flight surgeons' are key in developing mitigation strategies to ensure the safety, health and performance of space travellers in what is an extreme and hazardous environment. This includes all phases from selection, training and spaceflight itself to post-flight rehabilitation and long-term health. The recent recognition of the speciality provides a pathway to train in this fascinating field of medicine and is a key enabler for the UK Government's commercial spaceflight ambition.

Acute exposure to altitude.

Acute exposure to altitude principally encompasses aviation and space activities. These environments can be associated with very acute changes in pressure, oxygenation and temperature due to rates and magnitude of ascent that are not experienced in more chronic exposure such as mountaineering. The four key physiological challenges during acute exposure to altitude are: hypoxia (and hyperventilation), gas volume changes, decompression sickness and cold. The brief nature of aviation exposure to altitude provides little opportunity for acclimatisation, leading to markedly different effects when an individual is exposed to the same altitude acutely compared with an acclimatised individual climbing an 8000m (26 347ft) peak. Challenges such as hypobaric decompression sickness are not considered a hazard for chronic altitude exposure but are routine considerations for those flying to high altitude. Protective systems are essential for aircrew and passengers to survive and function during acute exposure to altitude.

Is mild normobaric hypoxia a risk factor for venous thromboembolism?

BACKGROUND: Modern air travel entails a cabin altitude between 1520 and 2440 m (5000-8000 ft) and thus exposure to mild hypoxia. There is debate as to whether hypoxia is causally related to venous thromboembolism (VTE) occurring during or after travel. One study suggested that a short period of hypobaric hypoxia causes activation of coagulation. OBJECTIVES: To test the hypothesis that hypoxia alone (normobaric hypoxia) causes activation of coagulation, possibly through endothelial cell activation. METHODS: Six healthy male volunteers were exposed for 3 h, while seated, on two separate occasions to (i) dry air (control) and (ii) hypoxic gas mixture (12.8% O2 in N2, equivalent to breathing air at 3660 m [12000 ft]). RESULTS: There were no differences in hemostatic or endothelial markers between control and hypoxic groups, but platelet and leukocyte counts increased and were significantly higher in the hypoxic group. There were increases in fibrinogen and von Willebrand factor, as well as rheological changes, but these were not significantly different between control and hypoxic groups. CONCLUSIONS: This small study does not support the previous suggestion that hypoxia causes activation of coagulation, and suggests that immobility-induced rheological changes may be more significant in the etiology of VTE occurring during or after travel.